EDITORIAL SECTION

Articles

The Impact of AI and Machine Learning on Drug Discovery

Now and then an industry hits a point where the old ways no matter how trusted start to feel a bit like trying to run a marathon in hiking boots Drug discovery is in that spot For decades pharmaceutical RD leaned heavily on long painstaking experiments and the occasional stroke of luck Entire teams would spend years nudging molecules around waiting for a hint that something might work After all th...

Pharmaceutical Marketing in the Digital Age: Strategies and Challenges

Currently there is a great advancement in the use of technological solutions particularly under the modern pharma digital era Therefore with increase in knowledge dissemination through internet among the citizenry due to enhanced technology

Considerations and Functional Elements of Closed Systems: Isolators and Single Use Systems

Advances in technology have demonstrated the feasibility of using isolators and singleuse systems SUS in routine pharmaceutical manufacturing operations particularly in aseptic processing Their implementation has significantly reduced the risk of chemical particulate and microbiological contamination

The Unprecedented Surge of Biopharmaceuticals in the European Market

Recent years have seen a significant upheaval in the European pharmaceutical scene marked by an unparalleled surge in biopharmaceutical prominence This shift isnt fleeting but signifies a profound and enduring transformation To fully grasp this paradigm shift its essential to explore the complex interplay of scientific advancements market dynamics regulatory frameworks economic factors and global...

The Cost of Uncertainty: How Analytical Chemistry Drives Billion-Dollar Decisions in Pharma

In pharmaceutical development uncertainty is not an abstract scientific inconvenience It has a cost a timeline a regulatory consequence and ultimately a patient impact A promising medicine may have strong biological rationale compelling early data and significant commercial potential yet still face a fundamental question do we truly understand the product well enough to develop manufacture approve...

The Architect of the Void: When 3D Printing Becomes the Body’s New Bone

In the quiet pressurised hum of a modern surgical suite a surgeon holds a highdefinition scan of a young patients femur On the screen a jagged dark shadow marks where an osteosarcoma has claimed its territory For decades the script for this moment has been written in cold hard steel

Techno Trends

Lilly’s Olomorasib Gains FDA Breakthrough Therapy Status

Eli Lilly and Company has secured Breakthrough Therapy designation from the US Food and Drug Administration FDA for olomorasib an investigational medicine being developed for adults with advanced pancreatic cancer carrying a KRAS GC mutation

Projects

Resilience and Lilly Expand Ohio Manufacturing Facility with US$750 Million Investment

Resilience a technologydriven contract development and manufacturing organisation CDMO has expanded its strategic partnership with Eli Lilly and Company to increase domestic production

Research Insights

Induction of osteogenic differentiation of MSCs by GSK3β knockdown through GSK3β siRNAs transfection

The development of effective strategies for treating bone defects can be based on gene therapy methods aimed at regulating the differentiation of osteoprogenitor cells One of the approaches is to use siRNA mo

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys